Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic model. (Record no. 30893839)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01142 a2200313 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250518100503.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 202105s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 1592-8721 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.3324/haematol.2019.242289 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Kloos, Robin Q H |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20210527 |
| 245 00 - TITLE STATEMENT | |
| Title | Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic model. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | Haematologica |
| Date of publication, distribution, etc. | 05 2021 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1254-1261 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Journal Article; Research Support, Non-U.S. Gov't |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Asparaginase |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Child |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Databases, Factual |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drug Monitoring |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Models, Biological |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Precursor Cell Lymphoblastic Leukemia-Lymphoma |
| General subdivision | drug therapy |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mathôt, Ron |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Pieters, Rob |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | van der Sluis, Inge M |
| 773 0# - HOST ITEM ENTRY | |
| Title | Haematologica |
| Related parts | vol. 106 |
| -- | no. 5 |
| -- | p. 1254-1261 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.3324/haematol.2019.242289">https://doi.org/10.3324/haematol.2019.242289</a> |
| Public note | Available from publisher's website |
No items available.